Why Paediatric Brain Tumours?
Brain tumours remain the most common cause of cancer-related death in children. Limited progress in these diseases relates directly to the use of inaccurate preclinical pipelines that fail to identify drugs with activity in patients. Accurate preclinical pipelines are especially important for rare cancers, such as paediatric brain tumours, that have small patient populations available for study. Thus, curing brain tumours in children will require new approaches that leverage a deep understanding of tumour biology to design disease-specific therapies.
What is the CRUK-CBTCE?
In April 2018, Cancer Research UK (CRUK) launched the CRUK Children’s Brain Tumour Centre of Excellence (CRUK-CBTCE) to drive progress in paediatric brain cancer research.
The CRUK-CBTCE convenes a critical mass of expert personnel, infrastructure and global collaborations in paediatric brain tumour biology, medicinal chemistry, pharmacology, and preclinical and clinical trials. The Centre fosters global reach and unites its members through an international community of aligned experts, the International Children’s Brain Tumour Board (ICBTB).
To forge an innovative four-stage pipeline that generates curative treatments for children with brain tumours.
To transform the way the world develops treatments for children with brain tumours.
OUR RESEARCH STRATEGY
Centred around our biology, drug discovery and development pipeline, this will leverage the expertise of the brightest minds in the paediatric brain tumour field.
INTERNATIONAL CHILDREN’S BRAIN TUMOUR BOARD (ICBTB)
Direct collaboration with world leaders in paediatric brain tumour and drug development research communities.